Managed by Brandon Capital, Brandon BioCatalyst supports the development and commercialisation of early-stage biomedical discoveries originating from member research organisations, providing both capital and expertise to guide the successful development of new therapies.
Brandon BioCatalyst is a unique collaboration of investors, CSL, government and more than 50 leading medical research institutes and hospitals united by a single purpose: generating cutting edge, next generation medical therapies and technologies to improve health and save lives.
50+ Medical research institutes and hospitals
ACT Government
NSW Government Health
Government of South Australia
Queensland Government
Victorian Government
Western Australian Government
Ministry of Business, Innovation & Employment (MBIE) NZ
Brandon Capital
Australian Government
Australian Super
Hesta
Host Plus
TelstraSuper
CSL
The John Curtin School of Medical Research (JCSMR) is a multi-disciplinary institute. We excel in ground-breaking medical research in Cancer Biology; Immunology and Infectious diseases; Genomics; and Neuroscience.
ViewSince its inception in 1956, the Auckland Cancer Society Research Centre (ACSRC) has published nearly 1,000 papers in international scientific and medical journals, and filed more than 100 patent applications for new anti-cancer drugs.
ViewThe Brain Health Research Centre is one of the pre‐eminent neuroscience centres in NZ. It consists of more than 40 research groups (academic & clinical), plus their research staff and students across a number of schools and campuses in the Divisions of Health Sciences and Sciences at the University of Otago. The mission of the Brain Health Research Centre (BHRC) is to support excellent, international quality research at the University of Otago, aimed at understanding the mechanisms of brain health, disease and repair, including the development of new treatments for neurological disorders.
Brandon Capital manages Brandon BioCatalyst, providing seed and venture capital investment to support the development and international growth of Australian and New Zealand life science companies.
Brandon Capital website
Through the internship it was fantastic to understand what Brandon are looking for in the projects they fund. The learnings from the internship program will be applied to the new projects we develop, both in reviewing the opportunity and developing a solid business plan that will increase the commercial success.
The internship was a valuable experience that filled a critical gap in my knowledge of how early-stage life science technologies are commercialised. Up to this point, my experience was from a technology development perspective, and I did not have a full understanding of what investors were seeking in potential investments. The internship experience is immeasurable and will pay dividends well into the future.
The internship was an excellent learning and development opportunity. I greatly improved my understanding of the venture capital financing model and elements such as valuation, due diligence, market analysis and drug development. The MRCF internship program also enabled me to expand my national commercialisation networks and work alongside experienced biotech investors.
